OMPI Pengajuan SEC - Obagi Medical Products, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1375247

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Obagi Medical Products, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

May 13, 2013	SC 13D/A	OMPI / Obagi Medical Products, Inc. / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Obagi Medical Products, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67423R108 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone
May 6, 2013	15-12B	- FORM 15 Form 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-33204 OBAGI MEDICAL PRODUCTS, INC. (Exact name of registrant as
April 26, 2013	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets 8-K 1 d527102d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2013 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33204 22-3904668 (State or other jurisdic
April 26, 2013	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OBAGI MEDICAL PRODUCTS, INC. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OBAGI MEDICAL PRODUCTS, INC. FIRST: The name of the Corporation is Obagi Medical Products, Inc. (hereinafter the “Corporation”). SECOND: The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, Wilmington, County of New Castle, 19801. The name of its registered agent at that addre
April 26, 2013	S-8 POS	- S-8 POS S-8 POS As filed with the Securities and Exchange Commission on April 26, 2013 Registration No.
April 26, 2013	EX-3.2	THIRD AMENDED AND RESTATED BY-LAWS OBAGI MEDICAL PRODUCTS, INC. A Delaware Corporation Effective April 25, 2013 TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 2 EX-3.2 Exhibit 3.2 THIRD AMENDED AND RESTATED BY-LAWS OF OBAGI MEDICAL PRODUCTS, INC. A Delaware Corporation Effective April 25, 2013 TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 2 Section 1. Place of Meetings 2 Section 2. Annual Meetings 2 Section 3. Special Meetings 2 Section 4. Notice 3 Section 5. Adjour
April 26, 2013	S-8 POS	- S-8 POS S-8 POS As filed with the Securities and Exchange Commission on April 26, 2013 Registration No.
April 25, 2013	SC TO-T/A	- SC TO-T/A SC TO-T/A 1 d528280dsctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 7) OBAGI MEDICAL PRODUCTS, INC. (Name of Subject Company (Issuer)) Odysseus Acquisition Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a
April 25, 2013	SC 14D9/A	- SC 14D9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT No. 9) OBAGI MEDICAL PRODUCTS, INC. (Name of Subject Company) OBAGI MEDICAL PRODUCTS, INC. (Name of Person(s) Filing Statement) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 6
April 25, 2013	EX-99.(A)(5)(H)	VALEANT PHARMACEUTICALS INTERNATIONAL, INC. COMPLETES TENDER OFFER FOR OBAGI MEDICAL PRODUCTS, INC. EX-99.(a)(5)(H) Exhibit (a)(5)(H) International Headquarters 2150 St. Elzéar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Laurie W. Little 949-461-6002 [email protected] VALEANT PHARMACEUTICALS INTERNATIONAL, INC. COMPLETES TENDER OFFER FOR OBAGI MEDICAL PRODUCTS, INC. Laval, Quebec — April 25, 2013 — Valeant Pharmaceuticals International, Inc
April 24, 2013	10-K/A	Annual Report - FORM10KA 123112 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-
April 24, 2013	SC TO-T/A	- SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 6) OBAGI MEDICAL PRODUCTS, INC. (Name of Subject Company (Issuer)) Odysseus Acquisition Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Valeant Pharma
April 24, 2013	EX-99.(A)(5)(G)	VALEANT PHARMACEUTICALS INTERNATIONAL, INC. ANNOUNCES RECEIPT OF APPROVAL FROM THE ANTIMONOPOLY COMMITTEE OF UKRAINE FOR ITS PREVIOUSLY ANNOUNCED ACQUISITION OF OBAGI MEDICAL PRODUCTS, INC. EX-(a)(5)(G) Exhibit (a)(5)(G) International Headquarters 2150 St. Elzéar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Laurie W. Little 949-461-6002 [email protected] VALEANT PHARMACEUTICALS INTERNATIONAL, INC. ANNOUNCES RECEIPT OF APPROVAL FROM THE ANTIMONOPOLY COMMITTEE OF UKRAINE FOR ITS PREVIOUSLY ANNOUNCED ACQUISITION OF OBAGI MEDICAL PRO
April 24, 2013	SC 14D9/A	- AMENDMENT NUMBER 8 TO SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT No. 8) OBAGI MEDICAL PRODUCTS, INC. (Name of Subject Company) OBAGI MEDICAL PRODUCTS, INC. (Name of Person(s) Filing Statement) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 6
April 23, 2013	EX-99.(A)(5)(F)	VALEANT PHARMACEUTICALS ANNOUNCES EXTENSION OF THE EXPIRATION DATE FOR ITS PREVIOUSLY ANNOUNCED TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF OBAGI MEDICAL PRODUCTS, INC. EX-99.(A)(5)(F) Exhibit (a)(5)(F) International Headquarters 2150 St. Elzéar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Laurie W. Little 949-461-6002 [email protected] VALEANT PHARMACEUTICALS ANNOUNCES EXTENSION OF THE EXPIRATION DATE FOR ITS PREVIOUSLY ANNOUNCED TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF OBAGI MEDICAL PRODUC
April 23, 2013	SC TO-T/A	- SC TO-T/A #5 SC TO-T/A #5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 5) OBAGI MEDICAL PRODUCTS, INC. (Name of Subject Company (Issuer)) Odysseus Acquisition Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of V
April 23, 2013	SC 14D9/A	- AMENDMENT NUMBER 7 TO SCHEDULE 14D-9 Amendment Number 7 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 22, 2013	SC TO-T/A	- SC TO-T/A #4 SC TO-T/A #4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 4) OBAGI MEDICAL PRODUCTS, INC. (Name of Subject Company (Issuer)) Odysseus Acquisition Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of V
April 22, 2013	CORRESP	- Correspondence Letter April 22, 2013 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
April 22, 2013	EX-99.(A)(5)(E)	VALEANT PHARMACEUTICALS ANNOUNCES RECEIPT OF ANTITRUST CLEARANCE IN THE UNITED STATES FOR ITS PREVIOUSLY ANNOUNCED ACQUISITION OF OBAGI MEDICAL PRODUCTS, INC. EX-99.(A)(5)(E) Exhibit (a)(5)(E) International Headquarters 4787 Levy Street Montreal, Quebec, H4R 2P9 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Laurie W. Little 949-461-6002 [email protected] VALEANT PHARMACEUTICALS ANNOUNCES RECEIPT OF ANTITRUST CLEARANCE IN THE UNITED STATES FOR ITS PREVIOUSLY ANNOUNCED ACQUISITION OF OBAGI MEDICAL PRODUCTS, INC. Montreal, Quebec — Apr
April 22, 2013	SC 14D9/A	- AMENDMENT NUMBER 6 TO SCHEDULE 14D-9 AMENDMENT NUMBER 6 to SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 17, 2013	SC 13D/A	OMPI / Obagi Medical Products, Inc. / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Obagi Medical Products, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67423R108 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone
April 12, 2013	SC TO-T/A	- SC TO-T/A #3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 3) OBAGI MEDICAL PRODUCTS, INC. (Name of Subject Company (Issuer)) Odysseus Acquisition Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Valeant Pharma
April 12, 2013	SC 14D9/A	- AMENDMENT NUMBER 5 TO SCHEDULE 14D-9 Amendment Number 5 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 5, 2013	SC TO-T/A	- SC TO-T/A #2 SC TO-T/A #2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) OBAGI MEDICAL PRODUCTS, INC. (Name of Subject Company (Issuer)) Odysseus Acquisition Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of V
April 5, 2013	SC 14D9/A	- AMENDMENT NUMBER 4 TO SCHEDULE 14D-9 Amendment Number 4 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 4, 2013	CORRESP	- SEC Letter SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP FOUR TIMES SQUARE NEW YORK 10036-6522 TEL: (212) 735-3000 FAX: (212) 735-2000 www.
April 4, 2013	EX-99.(A)(5)(D)	April 3, 2013 EX-99.(a)(5)(D) Exhibit (a)(5)(D) April 3, 2013 Dear Obagi Stockholders: I am pleased to inform you that Valeant Pharmaceuticals International (“VPI”), Odysseus Acquisition Corp. (“Purchaser”), Obagi Medical Products, Inc. (“Obagi”) and Valeant Pharmaceuticals International, Inc. (“Valeant”) have agreed to increase the Offer Price from $19.75 to $24.00 in cash for each share of Obagi common stock
April 4, 2013	SC 14D9/A	- AMENDMENT NUMBER 3 TO SCHEDULE 14D-9 Amendment Number 3 to Schedule 14D-9 Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 4, 2013	SC TO-T/A	- SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) OBAGI MEDICAL PRODUCTS, INC. (Name of Subject Company (Issuer)) Odysseus Acquisition Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Vale
April 4, 2013	EX-99.(A)(5)(C)	International Headquarters EX-99.(A)(5)(C) Exhibit (a)(5)(c) International Headquarters 4787 Levy Street Montreal, Quebec, H4R 2P9 Phone: 514.744.6792 Fax: 514.744.6272 VALEANT PHARMACEUTICALS AND OBAGI MEDICAL PRODUCTS AGREE ON AN INCREASED OFFER PRICE OF $24.00 PER SHARE IN CASH MONTREAL, April 3, 2013 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that Valeant and Obag
April 3, 2013	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2013 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33204 22-3904668 (State or other jurisdiction of incorporation) (Com
April 3, 2013	EX-99.1	Obagi Medical Products, Inc. and Valeant Pharmaceuticals, Inc. Agree on an Increased Offer Price of $24.00 per Share in Cash EX-99.1 Exhibit 99.1 Obagi Medical Products, Inc. and Valeant Pharmaceuticals, Inc. Agree on an Increased Offer Price of $24.00 per Share in Cash LONG BEACH, Calif — April 3, 2013 — Obagi Medical Products, Inc. (NASDAQ: OMPI) (the “Company” or “Obagi”) today announced that Obagi and Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) have executed an amendment to their Agreement a
April 3, 2013	EX-2.1	AMENDMENT TO AGREEMENT AND PLAN OF MERGER EX-2.1 Exhibit 2.1 AMENDMENT TO AGREEMENT AND PLAN OF MERGER This AMENDMENT, dated as of April 3, 2013 (this “Amendment”), to the AGREEMENT AND PLAN OF MERGER, dated as of March 19, 2013 (the “Merger Agreement”), made among Valeant Pharmaceuticals International, a Delaware corporation (“Parent”), Odysseus Acquisition Corp., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Su
April 3, 2013	SC 14D9/A	- AMENDMENT NUMBER 2 TO SCHEDULE 14D-9/A Amendment Number 2 to Schedule 14D-9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 2, 2013	SC TO-C	- SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Obagi Medical Products, Inc. (Name of Subject Company) Snow White Acquisition Corp. and Merz GmbH & Co. KGaA (Names of Filing Persons — Offeror) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Cl
April 2, 2013	EX-99.1	2 Exhibit 99.1 PRESS RELEASE Merz Pharma GmbH & Co. KGaA Ute Weinhold Corporate Communications Eckenheimer Landstraße 100 GER-60318 Frankfurt am Main Tel + 49 - 69 - 15 03 - 889 [email protected] www.merz.de Merz Pharma Group Makes Superior Proposal to Acquire Obagi Medical Products Proposes to Acquire All of Obagi’s Outstanding Common Stock for $22 Per Share in Cash Transaction Not Conditioned U
April 2, 2013	SC 14D9/A	- AMENDMENT NUMBER 1 TO SCHEDULE 14D-9 Amendment Number 1 to Schedule 14D-9 SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 28, 2013	SC 13D	OMPI / Obagi Medical Products, Inc. / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Obagi Medical Products, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67423R108 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person A
March 26, 2013	EX-99.A.1.B	THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION Letter of Transmittal To Tender Shares of Common Stock Obagi Medical Products, Inc. $19.75 Per Share, Net in Cash, Pursuant to the Offer to Purchase dated March 26, 2013 Odysseus Acquis EX-99.a.1.B Exhibit (a)(1)(B) THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION Letter of Transmittal To Tender Shares of Common Stock of Obagi Medical Products, Inc. at $19.75 Per Share, Net in Cash, Pursuant to the Offer to Purchase dated March 26, 2013 by Odysseus Acquisition Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Val
March 26, 2013	SC TO-T	- SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 OBAGI MEDICAL PRODUCTS, INC. (Name of Subject Company (Issuer)) Odysseus Acquisition Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Valeant Pharmaceuticals Internat
March 26, 2013	EX-99.A.1.C	Notice of Guaranteed Delivery Offer to Purchase All Outstanding Shares of Common Stock Obagi Medical Products, Inc. $19.75 Per Share, Net in Cash, Pursuant to the Offer to Purchase dated March 26, 2013 Odysseus Acquisition Corp. a wholly owned subsid EX-99.a.1.C Exhibit (a)(1)(C) Notice of Guaranteed Delivery for Offer to Purchase All Outstanding Shares of Common Stock of Obagi Medical Products, Inc. at $19.75 Per Share, Net in Cash, Pursuant to the Offer to Purchase dated March 26, 2013 by Odysseus Acquisition Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Valeant Pharmaceuticals Internat
March 26, 2013	EX-99.A.5.B	Notice of Offer to Purchase All Outstanding Shares of Common Stock Obagi Medical Products, Inc. $19.75 Per Share, Net in Cash, Pursuant to the Offer to Purchase dated March 26, 2013 Odysseus Acquisition Corp. a wholly owned subsidiary of Valeant Phar EX-99.a.5.B Exhibit (a)(5)(B) Summary Advertisement This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely pursuant to the Offer to Purchase, dated March 26, 2013, and the related Letter of Transmittal, and any amendments or supplements to such Offer to Purchase or Letter of Transmittal. The Pu
March 26, 2013	EX-99.A.1.F	Request for Taxpayer Identification Number and Certification EX-99.a.1.F Exhibit (a)(1)(F) Form W-9 (Rev. December 2011) Department of the Treasury Internal Revenue Service Request for Taxpayer Identification Number and Certification Give Form to the requester. Do not send to the IRS. Name (as shown on your income tax return) Print or type See Specific Instructions on page 4. Business name/disregarded entity name, if different from above Check appropriate b
March 26, 2013	SC 14D9	- SC 14D9 SC 14D9 Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 OBAGI MEDICAL PRODUCTS, INC. (Name of Subject Company) OBAGI MEDICAL PRODUCTS, INC. (Name of Person(s) Filing Statement) Common Stock, Par Value $0.001 Per Share (Title of Class of Secur
March 26, 2013	EX-99.A.1.D	Letter to Brokers and Dealers with Respect to Offer to Purchase All Outstanding Shares of Common Stock Obagi Medical Products, Inc. $19.75 Per Share, Net in Cash, Pursuant to the Offer to Purchase dated March 26, 2013 Odysseus Acquisition Corp. a who EX-99.a.1.D Exhibit (a)(1)(D) Letter to Brokers and Dealers with Respect to Offer to Purchase All Outstanding Shares of Common Stock of Obagi Medical Products, Inc. at $19.75 Per Share, Net in Cash, Pursuant to the Offer to Purchase dated March 26, 2013 by Odysseus Acquisition Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Valeant Pharmaceutic
March 26, 2013	EX-99.A.1.E	Letter to Clients with Respect to Offer to Purchase All Outstanding Shares of Common Stock Obagi Medical Products, Inc. $19.75 Per Share, Net in Cash, Pursuant to the Offer to Purchase dated March 26, 2013 Odysseus Acquisition Corp. a wholly owned su EX-99.a.1.E Exhibit (a)(1)(E) Letter to Clients with Respect to Offer to Purchase All Outstanding Shares of Common Stock of Obagi Medical Products, Inc. at $19.75 Per Share, Net in Cash, Pursuant to the Offer to Purchase dated March 26, 2013 by Odysseus Acquisition Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Valeant Pharmaceuticals Internat
March 26, 2013	EX-99.A.1.A	Offer To Purchase For Cash All Outstanding Shares of Common Stock Obagi Medical Products, Inc. $19.75 Per Share, Net in Cash, Odysseus Acquisition Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of V EX-99.a.1.A Table of Contents Exhibit (a)(1)(A) Offer To Purchase For Cash All Outstanding Shares of Common Stock of Obagi Medical Products, Inc. at $19.75 Per Share, Net in Cash, by Odysseus Acquisition Corp. a wholly owned subsidiary of Valeant Pharmaceuticals International a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:
March 25, 2013	SC 13G/A	OMPI / Obagi Medical Products, Inc. / Visium Asset Management, LP - AMENDMENT NO. 6 TO SCHEDULE 13G Passive Investment Amendment No. 6 to Schedule 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Obagi Medical Products, Inc. (Name of Issuer) COMMON STOCK, $0.001 PER SHARE (Title of Class of Securities) 67423R108 (CUSIP Number) March 15, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des
March 20, 2013	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 d507118d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2013 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33204 22-3904668 (State or other jurisdiction
March 20, 2013	EX-99	Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash Exhibit (a)(5)(A) Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash 03/20/2013 MONTREAL, March 20, 2013 /PRNewswire/ - Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Obagi
March 20, 2013	EX-2.1	AGREEMENT AND PLAN OF MERGER by and among VALEANT PHARMACEUTICALS INTERNATIONAL, ODYSSEUS ACQUISITION CORP., VALEANT PHARMACEUTICALS INTERNATIONAL, INC. OBAGI MEDICAL PRODUCTS, INC. Dated as of March 19, 2013 TABLE OF CONTENTS Page ARTICLE I The Offe Agreement and Plan of Merger Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among VALEANT PHARMACEUTICALS INTERNATIONAL, ODYSSEUS ACQUISITION CORP., VALEANT PHARMACEUTICALS INTERNATIONAL, INC. and OBAGI MEDICAL PRODUCTS, INC. Dated as of March 19, 2013 TABLE OF CONTENTS Page ARTICLE I The Offer SECTION 1.1 The Offer 2 SECTION 1.2 Offer Documents 3 SECTION 1.3 Offer Funds 4 SECTI
March 20, 2013	EX-99.1	Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. For $19.75 per Share in Cash Press Release of Obagi Medical Products, Inc., dated March 20, 2013 Exhibit 99.1 Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. For $19.75 per Share in Cash LONG BEACH, Calif — (Business Wire) — March 20, 2013 — Obagi Medical Products, Inc (NASDAQ: OMPI) (the “Company” or “Obagi”) today announced that it entered into a definitive merger agreement with Va
March 20, 2013	SC TO-C	- SC TO-C FOR VALEANT PHARMACEUTICALS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 OBAGI MEDICAL PRODUCTS, INC. (Name of Subject Company (Issuer)) ODYSSEUS ACQUISITION CORP. A Wholly Owned Subsidiary of VALEANT PHARMACEUTICALS INTERNATIONAL A Wholly Owned Subsidiary of VALEANT PHARMACEUTICALS INTERNAT
March 20, 2013	SC14D9C	- SC14D9C SC14D9C 1 d507128dsc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 OBAGI MEDICAL PRODUCTS, INC. (Name of Subject Company) OBAGI MEDICAL PRODUCTS, INC. (Names of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Clas
March 15, 2013	EX-10.35	2013 PERFORMANCE INCENTIVE PLAN (the “Plan”) Exhibit 10.35 2013 PERFORMANCE INCENTIVE PLAN (the “Plan”) The 2013 Performance Incentive Plan amends, restates and is the successor plan to the 2012 Performance Incentive Plan, each of which was adopted under the Obagi Medical Products, Inc. 2005 Stock Incentive Plan. PLAN PARTICIPANTS All regular, full-time employees of Obagi Medical Products (the “Company”) who have been notified in writing of
March 15, 2013	EX-10.36	Form of Amendment Amended and Restated Executive Employment Agreement Exhibit 10.36 Form of Amendment to Amended and Restated Executive Employment Agreement This Amendment to Amended and Restated Executive Employment Agreement (the “Amendment”) is entered into and effective as of the 11th day of March 2013 (the “Amendment Date”) by and between Obagi Medical Products, Inc., a Delaware corporation (the “Company”), and, an individual resident of the State of California
March 15, 2013	EX-10.21	Executive Employment Agreement Exhibit 10.21 Executive Employment Agreement This Executive Employment Agreement (this “Agreement”), is executed and delivered effective as of August 15, 2013 (the “Effective Date”), by and between Obagi Medical Products, Inc., a Delaware corporation (the “Company”), and Mark T. Taylor, an individual resident of the State of California (“Executive”). 1. Position And Responsibilities (a) Position.
March 15, 2013	EX-10.33	PHEASANT HOLLOW BUSINESS PARK SOUTH JORDAN GATEWAY BLVD. SOUTH JORDAN, UTAH Exhibit 10.33 WAREHOUSE LEASE AGREEMENT PHEASANT HOLLOW BUSINESS PARK SOUTH JORDAN GATEWAY BLVD. SOUTH JORDAN, UTAH THIS Lease Agreement (the “Lease”) is made and entered into by and between PHEASANT HOLLOW BUSINESS PARK , L.L.C., a Utah limited liability company (“Landlord”), and OPO INC., a Delaware corporation (Tax I.D. #45-4321115), (“Tenant”) this 18th day of April, 2012 (the “Effective Date”
March 15, 2013	EX-10.8	Director Compensation for Non-Employee Members of Board (effective as of July 30, 2012) Exhibit 10.8 Director Compensation for Non-Employee Members of Board (effective as of July 30, 2012) Cash Compensation Retainer per qtr Annual Board Retainer (payable quarterly in advance) $ 35,000 $ 8,750 Annual Audit Committee Chair Retainer (payable quarterly in advance) $ 15,000 $ 3,7500 Annual Compensation and Nominating & Corporate Governance Committee Chair Retainer (payable quarterly in ad
March 15, 2013	EX-10.38	Amendment to Software License, Development and Services Agreement Exhibit 10.38 Amendment to Software License, Development and Services Agreement This Amendment to Software License, Development and Services Agreement (“Amendment”) is entered into as of the 6th day of March 2013 (the “Amendment Date”) by and among OPO, Inc., a Delaware corporation (“OPO”), and Koogly, LLC, an Arizona limited liability company (“Newco”). All capitalized terms used but not otherwis
March 15, 2013	EX-10.37	Amendment to Obagi Medical Products, Inc. 2005 Stock Incentive Plan, as Amended March 11, 2013 Whereas, the Board of Directors of Obagi Medical Products, Inc. (the “Company”) adopted the 2005 Stock Incentive Plan on November 17, 2005, which has been Exhibit 10.37 Amendment to Obagi Medical Products, Inc. 2005 Stock Incentive Plan, as Amended March 11, 2013 Whereas, the Board of Directors of Obagi Medical Products, Inc. (the “Company”) adopted the 2005 Stock Incentive Plan on November 17, 2005, which has been subsequently amended in November 2006 and April 2010 (the “Plan”), and now wishes to amend certain provisions of the Plan as set forth b
March 15, 2013	10-K	Annual Report - FORM 10K 123112 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33204 OBAGI MEDICAL
March 14, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - OBAGI MEDICAL PRODUCTS, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2013 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction
March 14, 2013	EX-99.1	Obagi Medical Products Reports Fourth Quarter and Year-End 2012 Financial Results --Conference Call To Be Held at 4:30 PM ET Today-- Exhibit 99.1 Obagi Medical Products Reports Fourth Quarter and Year-End 2012 Financial Results -Conference Call To Be Held at 4:30 PM ET Today- LONG BEACH, Calif.-(BUSINESS WIRE)-March 14, 2013-Obagi Medical Products, Inc. (NASDAQ: OMPI), a leader in topical aesthetic and therapeutic skin health systems, today reported financial results for the fourth quarter and full-year ended December 31, 2012.
March 8, 2013	SC 13G/A	OMPI / Obagi Medical Products, Inc. / Visium Asset Management, LP - AMENDMENT NO.5 TO SCHEDULE 13G Passive Investment Amendment No.5 to Schedule 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Obagi Medical Products, Inc. (Name of Issuer) COMMON STOCK, $0.001 PER SHARE (Title of Class of Securities) 67423R108 (CUSIP Number) February 26, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d
February 14, 2013	SC 13G/A	OMPI / Obagi Medical Products, Inc. / Visium Asset Management, LP - SCHEDULE 13G (AMENDMENT NO. 4) Passive Investment SC 13G/A 1 d487123dsc13ga.htm SCHEDULE 13G (AMENDMENT NO. 4) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Obagi Medical Products, Inc. (Name of Issuer) COMMON STOCK, $0.001 PER SHARE (Title of Class of Securities) 67423R108 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement)
February 13, 2013	SC 13G	OMPI / Obagi Medical Products, Inc. / VANGUARD GROUP INC Passive Investment obagimedicalproductsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: Obagi Medical Products Inc Title of Class of Securities: Common Stock CUSIP Number: 67423R108 Date of Event Which Requires Filing of this Statement: December 31, 2012 Check the a
February 13, 2013	SC 13G/A	OMPI / Obagi Medical Products, Inc. / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #1 Under the Securities and Exchange Act of 1934 Obagi Medical Products, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67423R108 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S
February 13, 2013	EX-99.II	to Schedule 13G Joint Filing Agreement EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 12, 2013 in connection with their beneficial ownership of Obagi Medical Products, Inc. Each of Columbia Small Cap Value Fund I and Columbia Management Investment Advisers, LLC authorizes Ameriprise Financial, Inc. to execute th
February 13, 2013	EX-99.I	to Schedule 13G EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.
December 10, 2012	EX-99.1	Obagi Medical Confirms Receipt of Directors Nomination Notice from Voce Capital Exhibit 99.1 FOR IMMEDIATE RELEASE Obagi Medical Confirms Receipt of Directors Nomination Notice from Voce Capital LONG BEACH, California—December 10, 2012—Obagi Medical Products, Inc. ("Obagi" or the "Company") (NASDAQ: OMPI), a leader in topical aesthetic and therapeutic skin health systems, today confirmed that Voce Capital has submitted to the Company a notice of intent to nominate a slate of
December 10, 2012	DEFA14A	- DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
December 10, 2012	8-K	Financial Statements and Exhibits - FORM 8K VOCE RESPONSE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2012 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdicti
December 10, 2012	EX-99.2	IMPORTANT ADDITIONAL INFORMATION Exhibit 99.2 IMPORTANT ADDITIONAL INFORMATION Obagi Medical Products, Inc. (“Obagi”) , its directors and certain of its executive officers may be deemed to be participants in the solicitation of proxies from Obagi stockholders in connection with the matters to be considered at Obagi’s 2013 Annual Meeting of Stockholders. Obagi intends to file a proxy statement with the U.S. Securities and Exchange
December 3, 2012	EX-99	VOCE CATALYST PARTNERS LP, VOCE CAPITAL LLC, VOCE CAPITAL MANAGEMENT LLC AND J. DANIEL PLANTS (COLLECTIVELY, “ EXHIBIT 2 VOCE CATALYST PARTNERS LP, VOCE CAPITAL LLC, VOCE CAPITAL MANAGEMENT LLC AND J.
December 3, 2012	EX-99	VOCE CAPITAL LAUNCHES PROXY CONTEST TO REPLACE OBAGI BOARD Voce Nominates Six Independent Directors, Demands Early Meeting EXHIBIT 1 VOCE CAPITAL LAUNCHES PROXY CONTEST TO REPLACE OBAGI BOARD Voce Nominates Six Independent Directors, Demands Early Meeting SAN FRANCISCO – December 3, 2012 – Voce Capital Management LLC (“Voce”), which led the successful campaign to defeat the poison pill at the 2012 annual meeting of Obagi Medical Products, Inc.
December 3, 2012	DFAN14A	- OBAGI MEDICAL PRODUCTS, INC. DFAN14A 1 p12-1908dfan14a.htm OBAGI MEDICAL PRODUCTS, INC. SCHEDULE 14A Consent Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [ ] Filed by a Party other than the Registrant [x] Check the appropriate box: [ ] Preliminary Consent Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Defi
November 1, 2012	EX-99.1	Obagi Medical Products Reports Third Quarter 2012 Earnings; Company Provides Update to Key Initiatives --Conference Call To Be Held at 4:30 PM EDT Today-- Exhibit 99.1 Obagi Medical Products Reports Third Quarter 2012 Earnings; Company Provides Update to Key Initiatives -Conference Call To Be Held at 4:30 PM EDT Today- LONG BEACH, Calif.-(BUSINESS WIRE)-November 1, 2012-Obagi Medical Products, Inc. (NASDAQ: OMPI), a leader in topical aesthetic and therapeutic skin health systems, today reported financial results for the third quarter and nine months
November 1, 2012	EX-3.3	Secretary’s Certificate Amendment to Second Amended and restated Bylaws Exhibit 3.3 Secretary’s Certificate Amendment to Second Amended and restated Bylaws The undersigned hereby certifies that the undersigned is the duly elected, qualified and acting Secretary of Obagi Medical Products, Inc. (the “Company”), and that on October 30, 2012 , at a duly called and held meeting of the Board of Directors (the “Board”) of the Company, the Board adopted the following amendmen
November 1, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a50462857.htm OBAGI MEDICAL PRODUCTS, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2012 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Nu
November 1, 2012	10-Q	Quarterly Report - FORM 10Q 093012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33204 OBAGI
October 29, 2012	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 form8kcna.htm CNA SETTLEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2012 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-
October 29, 2012	EX-10.1	CONFIDENTIAL SETTLEMENT AGREEMENT AND RELEASE CONFIDENTIAL SETTLEMENT AGREEMENT AND RELEASE This Settlement Agreement and Release (“Agreement”) is made and entered as of the 23rd day of October 2012 (the “Effective Date”) by and between National Fire Insurance Company of Hartford (“National Fire”) and American Casualty Company of Reading, PA (“American Casualty”), on the one side, and OMP, Inc.
September 4, 2012	10-K/A	Annual Report - OBAGI MEDICAL PRODUCTS FORM 10KA 123111 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-
September 4, 2012	EX-10.34	SOFTWARE LICENSE, DEVELOPMENT AND SERVICES AGREEMENT Exhibit 10.34 THE CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST IN ACCORDANCE WITH RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. REDACTED PORTIONS OF THIS EXHIBIT ARE INDICATED BY AN [##] SOFTWARE LICENSE, DEVELOPMENT AND SERVICES AGREEMENT This Software License,
September 4, 2012	EX-10.35	Supply and Distribution Agreement Exhibit 10.35 THE CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST IN ACCORDANCE WITH RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. REDACTED PORTIONS OF THIS EXHIBIT ARE INDICATED BY AN [##] Supply and Distribution Agreement This Supply and Distribution Agreement ("
September 4, 2012	CORRESP	- September 4, 2012 Via EDGAR UNITED STATES SECURITIES AND EXCHANGE COMMISSION 450 Fifth Street, N.
August 16, 2012	8-K	Financial Statements and Exhibits - FORM 8-K APPOINTMENT OF SENIOR VICE PRESIDENT CORPORATE DEVELOPMENT AND INVESTOR RELATIONS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2012 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction
August 16, 2012	EX-99.1	Obagi Medical Products Appoints Mark Taylor as Senior Vice President Corporate Development and Investor Relations Obagi Medical Products Appoints Mark Taylor as Senior Vice President Corporate Development and Investor Relations LONG BEACH, Calif.
August 2, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - OBAGI MEDICAL PRODUCTS FORM 8K 063012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2012 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction
August 2, 2012	EX-99.1	Obagi Medical Products’ Reports Second Quarter 2012 EPS Rose to $0.18 vs. $0.16 a Year Ago; Revenue Rose to $30.5 million --Conference Call To Be Held at 4:30 PM EDT Today-- Obagi Medical Products’ Reports Second Quarter 2012 EPS Rose to $0.18 vs. $0.16 a Year Ago; Revenue Rose to $30.5 million -Conference Call To Be Held at 4:30 PM EDT Today- LONG BEACH, Calif., August 2, 2012 - Obagi Medical Products, Inc. (NASDAQ: OMPI), a leader in topical aesthetic and therapeutic skin health systems, today reported financial results for the second quarter and six months ended Ju
August 2, 2012	10-Q	Quarterly Report - FORM 10Q 063012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33204 OBAGI MEDI
August 2, 2012	8-K	Financial Statements and Exhibits - FORM 8K_APPOINTMENT OF NEW BOARD MEMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2012 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction o
August 2, 2012	EX-99.1	KRISTINA M. LESLIE JOINS BOARD OF DIRECTORS OBAGI MEDICAL PRODUCTS KRISTINA M. LESLIE JOINS BOARD OF DIRECTORS OF OBAGI MEDICAL PRODUCTS LONG BEACH, Calif.—August 2, 2012- Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced the appointment of Kristina M. Leslie to its Board of Directors. Ms. Leslie was also appointed to the Company’s Audit Committee. Ms. Leslie currently serves on the boar
August 2, 2012	EX-10.1	2012 PERFORMANCE INCENTIVE PLAN (the “Plan”) 2012 PERFORMANCE INCENTIVE PLAN (the “Plan”) The 2012 Performance Incentive Plan amends, restates and is the successor plan to the 2011 Performance Incentive Plan, each of which was adopted under the Obagi Medical Products, Inc.
July 10, 2012	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits 8-K 1 form8k.htm STOCKHOLDER RIGHTS PLAN TERM UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2012 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Dela
July 10, 2012	EX-3.1	CERTIFICATE OF ELIMINATION OF THE SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF OBAGI MEDICAL PRODUCTS, INC. Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware CERTIFICATE OF ELIMINATION OF THE SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF OBAGI MEDICAL PRODUCTS, INC.
July 10, 2012	8-A12B/A	- AMENDMENT NO 2 STOCKHOLDERS RIGHTS PLAN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 2) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) Delaware 22-3904668 (State of incorporation or organization) (I.R.S. Employer Identification
June 6, 2012	8-K	Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Submission of Matters to a Vote of Security Holders - ANNUAL MEETING RESULTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2012 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction of
May 25, 2012	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 form8k.htm FORM 8K OBAGI MEDICAL PRODUCTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2012 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Del
May 25, 2012	EX-4.2	AMENDMENT NO. 1 TO RIGHTS AGREEMENT Exhibit 4.2 AMENDMENT NO. 1 TO RIGHTS AGREEMENT Obagi Medical Products, Inc., a Delaware corporation (the “Corporation”), and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company, as rights agent, hereby enter into this Amendment No. 1 (this “Amendment”) dated May 25, 2012 to the Rights Agreement between them dated December 23, 2011 (the “Rights Agent”). 1. Subs
May 25, 2012	8-A12B/A	- FORM 8-A12B/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No.1) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) Delaware 22-3904668 (State of incorporation or organization) (I.R.S. Employer Identification N
May 25, 2012	DEFA14A	- OBAGI MEDICAL PRODUCTS DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defi
May 25, 2012	EX-10.1	AMENDMENT NO. 1 TO RIGHTS AGREEMENT Exhibit 10.1 AMENDMENT NO. 1 TO RIGHTS AGREEMENT Obagi Medical Products, Inc., a Delaware corporation (the “Corporation”), and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company, as rights agent, hereby enter into this Amendment No. 1 (this “Amendment”) dated May 25, 2012 to the Rights Agreement between them dated December 23, 2011 (the “Rights Agent”). 1. Sub
May 4, 2012	10-Q	Quarterly Report - OBAGI MEDICAL PRODUCTS FORM 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33204 OBAGI MED
May 3, 2012	EX-99.1	Obagi Medical Products First Quarter 2012 Sales Rose 16% to a Record $30.8 Million; Highest Sales Quarter in Company History Obagi Medical Products First Quarter 2012 Sales Rose 16% to a Record $30.8 Million; Highest Sales Quarter in Company History LONG BEACH, Calif.—May 3, 2012 - Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, today reported that net sales for the first quarter ended March 31, 2012 rose 16% to a record $30.8 million from $26.5 million a ye
May 3, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - OBAGI MEDICAL PRODUCTS FORM 8K 033112 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2012 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction of
April 27, 2012	DEF 14A	- DEF 14A OBAGI MEDICAL PRODUCTS DEF 14A 1 def14a.htm DEF 14A OBAGI MEDICAL PRODUCTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commis
April 18, 2012	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - FORM 8K COMERICA AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2012 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction
April 18, 2012	EX-10.1	SECOND AMENDMENT TO AMENDED AND RESTATED REVOLVING CREDIT AND TERM LOAN AGREEMENT SECOND AMENDMENT TO AMENDED AND RESTATED REVOLVING CREDIT AND TERM LOAN AGREEMENT This Second Amendment to Amended and Restated Revolving Credit and Term Loan Agreement (“Amendment”) is made as of this 30th day of March, 2012, by and among the financial institutions from time to time signatory hereto (individually a “Lender,” and any and all such financial institutions collectively, the “Lenders”), Comerica Bank, as Administrative Agent for the Lenders (in such capacity, the “Agent”), Arranger, Syndication Agent and Documentation Agent, and Obagi Medical Products, Inc.
April 16, 2012	PRE 14A	- PRE 14A OBAGI MEDICAL PRODUCTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: ý Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
March 13, 2012	EX-99.1	Obagi: Strategic Direction Information Meetings Welcome to the Obagi Transformation We’ve been transforming women’s skin for more than 20 years. Now it’s our turn. SAFE HARBOR 1 Today’s presentation contains forward-looking statements that can be ide Obagi: Strategic Direction Information Meetings Welcome to the Obagi Transformation We’ve been transforming women’s skin for more than 20 years.
March 13, 2012	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2012 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction
March 8, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2012 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction o
March 8, 2012	10-K	Annual Report - OBAGI MEDICAL PRODUCTS FORM 10K 123111 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33204 OBAGI MEDICAL
March 8, 2012	EX-10.34	SOFTWARE LICENSE, DEVELOPMENT AND SERVICES AGREEMENT Exhibit 10.34 THE CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST IN ACCORDANCE WITH RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. REDACTED PORTIONS OF THIS EXHIBIT ARE INDICATED BY AN [##] SOFTWARE LICENSE, DEVELOPMENT AND SERVICES AGREEMENT This Software License,
March 8, 2012	EX-10.35	Supply and Distribution Agreement Exhibit 10.35 THE CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST IN ACCORDANCE WITH RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. REDACTED PORTIONS OF THIS EXHIBIT ARE INDICATED BY AN [##] Supply and Distribution Agreement This Supply and Distribution Agreement ("
March 8, 2012	EX-99.1	Obagi Medical Products Reports Sales and Earnings Growth For the Fourth Quarter and Year Ended December 31, 2011 -- Company Outlines New Channel Strategy -- -- Company Provides Regulatory Update -- Contact: Preston Romm CFO, EVP of Finance, Operations & Administration Obagi Medical Products, Inc.
February 23, 2012	SC 13G/A	OMPI / Obagi Medical Products, Inc. / Visium Asset Management, LP - SCHEDULE 13G AMENDMENT NO. 3 Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No 3)* Obagi Medical Products (Name of Issuer) COMMON STOCK, $.001 PER SHARE (Title of Class of Securities) 67423R108 (CUSIP Number) January 20, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
February 14, 2012	EX-99.(II)	to Schedule 13G Joint Filing Agreement Joint Filing Agreement Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 13, 2012 in connection with their beneficial ownership of Obagi Medical Products, Inc.
February 14, 2012	EX-99.(I)	to Schedule 13G Identification and Classification of the Subsidiary Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.
February 14, 2012	SC 13G	OMPI / Obagi Medical Products, Inc. / AMERIPRISE FINANCIAL INC - SCHEDULE 13G Passive Investment Schedule 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities and Exchange Act of 1934 Obagi Medical Products, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67423R108 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i
January 13, 2012	EX-1	TRANSACTIONS SINCE THE DATE OF THE MOST RECENT FILING ON SCHEDULE 13D EXHIBIT 1 TRANSACTIONS SINCE THE DATE OF THE MOST RECENT FILING ON SCHEDULE 13D The Reporting Persons engaged in the following transactions in shares of Common Stock of the Company since the date of the most recent filing on Schedule 13D.
January 13, 2012	SC 13D/A	OMPI / Obagi Medical Products, Inc. / DISCOVERY EQUITY PARTNERS, LP - SCHEDULE 13D (AMENDMENT NO.4) Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* OBAGI MEDICAL PRODUCTS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67423R108 (CUSIP Number) Michael R. Murphy Discovery Group I, LLC 191 North Wacker Drive Suite 1685 Chicago, Illinois 60606 Telephone Nu
January 13, 2012	EX-4	POWER OF ATTORNEY EXHIBIT 4 POWER OF ATTORNEY The undersigned, Michael R. Murphy, hereby appoints Mark Buckley his true and lawful attorney-in-fact and agent, with full power to execute and file with the United States Securities and Exchange Commission and any stock exchange or similar authority, for and on his behalf in any and all capacities, any and all reports required to be filed pursuant to Section 13 of the
January 13, 2012	EX-2	JOINT FILING AGREEMENT EXHIBIT 2 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Amendment No.
January 13, 2012	EX-3	POWER OF ATTORNEY EXHIBIT 3 POWER OF ATTORNEY The undersigned, Daniel J. Donoghue, hereby appoints Mark Buckley his true and lawful attorney-in-fact and agent, with full power to execute and file with the United States Securities and Exchange Commission and any stock exchange or similar authority, for and on his behalf in any and all capacities, any and all reports required to be filed pursuant to Section 13 of the
December 23, 2011	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2011 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdicti
December 23, 2011	8-A12B	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Obagi Medical Products, Inc. (Exact name of reg UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) Delaware 22-3904668 (State of incorporation or organization) (I.R.S. Employer Identification No.) 3760 Kilroy Air
December 23, 2011	EX-4.1	Obagi Medical Products, Inc. American Stock Transfer & Trust Company, LLC Rights Agreement Dated as of December 23, 2011 TABLE OF CONTENTS Page Number Section 1. Definitions 1 Section 2. Appointment of Rights Agent 7 Section 3. Issue of Right Certifi Exhibit 4.1 Obagi Medical Products, Inc. and American Stock Transfer & Trust Company, LLC Rights Agreement Dated as of December 23, 2011 TABLE OF CONTENTS Page Number Section 1. Definitions 1 Section 2. Appointment of Rights Agent 7 Section 3. Issue of Right Certificates 7 Section 4. Form of Right Certificates 9 Section 5. Execution, Countersignature and Registration 9 Section 6. Transfer, Split U
December 23, 2011	EX-3.1	CERTIFICATE OF DESIGNATIONS Series A Junior Participating Preferred Stock OBAGI MEDICAL PRODUCTS, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) Exhibit 3.1 CERTIFICATE OF DESIGNATIONS of Series A Junior Participating Preferred Stock of OBAGI MEDICAL PRODUCTS, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) Obagi Medical Products, Inc. (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), hereby certifies that the following resolution was ad
December 22, 2011	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* OBAGI MEDICAL PRODUCTS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67423R108 (CUSIP Number) Michael R. Murphy Discovery Group I, LLC 191 North Wacker Drive Suite 1685 Chicago, Illinois 60606 Telephone Nu
December 22, 2011	EX-3	POWER OF ATTORNEY EXHIBIT 3 POWER OF ATTORNEY The undersigned, Daniel J. Donoghue, hereby appoints Mark Buckley his true and lawful attorney-in-fact and agent, with full power to execute and file with the United States Securities and Exchange Commission and any stock exchange or similar authority, for and on his behalf in any and all capacities, any and all reports required to be filed pursuant to Section 13 of the
December 22, 2011	EX-1	TRANSACTIONS SINCE THE DATE OF THE MOST RECENT FILING ON SCHEDULE 13D EXHIBIT 1 TRANSACTIONS SINCE THE DATE OF THE MOST RECENT FILING ON SCHEDULE 13D The Reporting Persons engaged in the following transactions in shares of Common Stock of the Company since the date of the most recent filing on Schedule 13D.
December 22, 2011	EX-4	POWER OF ATTORNEY EXHIBIT 4 POWER OF ATTORNEY The undersigned, Michael R. Murphy, hereby appoints Mark Buckley his true and lawful attorney-in-fact and agent, with full power to execute and file with the United States Securities and Exchange Commission and any stock exchange or similar authority, for and on his behalf in any and all capacities, any and all reports required to be filed pursuant to Section 13 of the
December 22, 2011	EX-2	JOINT FILING AGREEMENT EXHIBIT 2 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Amendment No.
November 15, 2011	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* OBAGI MEDICAL PRODUCTS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67423R108 (CUSIP Number) Michael R. Murphy Discovery Group I, LLC 191 North Wacker Drive Suite 1685 Chicago, Illinois 60606 Telephone Nu
November 15, 2011	EX-4	POWER OF ATTORNEY EX-4 5 ex4.htm EXHIBIT 4 EXHIBIT 4 POWER OF ATTORNEY The undersigned, Michael R. Murphy, hereby appoints Mark Buckley his true and lawful attorney-in-fact and agent, with full power to execute and file with the United States Securities and Exchange Commission and any stock exchange or similar authority, for and on his behalf in any and all capacities, any and all reports required to be filed pursu
November 15, 2011	EX-3	POWER OF ATTORNEY EXHIBIT 3 POWER OF ATTORNEY The undersigned, Daniel J. Donoghue, hereby appoints Mark Buckley his true and lawful attorney-in-fact and agent, with full power to execute and file with the United States Securities and Exchange Commission and any stock exchange or similar authority, for and on his behalf in any and all capacities, any and all reports required to be filed pursuant to Section 13 of the
November 15, 2011	EX-2	JOINT FILING AGREEMENT EX-2 3 ex2.htm EXHIBIT 2 EXHIBIT 2 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Amendment No. 2 to Schedule 13D to which this Agreement is attached. Dated: November 15, 2011 DISCOVERY GROUP I, LLC for itself and as general partner of DISCOVERY EQUITY PARTNERS, L.P. By Michael R. Murphy* Michael R. Murphy Managing Member Daniel J. Donoghue* Daniel J. Donoghue Micha
November 15, 2011	EX-1	TRANSACTIONS DURING PAST 60 DAYS EXHIBIT 1 TRANSACTIONS DURING PAST 60 DAYS The Reporting Persons engaged in the following transactions in shares of Common Stock of the Company during the past 60 days.
November 9, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2011 Obagi Medical Pr UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2011 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdictio
November 9, 2011	EX-99.1	Obagi Medical Products Reports Third Quarter 2011 Results Net Income Rose to $4.4 Million; Earnings per Share Rose to $0.24 Announces New Strategic Initiatives -Investor Conference Call to Be Held at 4:30 PM EDT Today- Contact: Preston Romm CFO, EVP of Finance, Operations & Administration Obagi Medical Products, Inc.
November 9, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33204 OBAGI
August 5, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33204 OBAGI MEDI
August 5, 2011	EX-10.1	Executive Employment Agreement Exhibit 10.1 Executive Employment Agreement This Executive Employment Agreement (this “Agreement”), is executed and delivered effective as of April 21, 2011 (the “Effective Date”), by and between Obagi Medical Products, Inc., a Delaware corporation (the “Company”), and Albert F. Hummel, an individual resident of the State of California (“Executive”). 1. Position And Responsibilities (a) Position.
August 4, 2011	EX-99.1	Obagi Medical Products Reports Second Quarter 2011 Results Non-GAAP Net Income of $3.4 Million and Earnings per Share of $0.18 -Conference Call To Be Held at 4:30 PM EDT Today- Contact: Preston Romm CFO, EVP of Finance, Operations & Administration Obagi Medical Products, Inc.
August 4, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2011 Obagi Medical Prod UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2011 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction
June 7, 2011	8-K	Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2011 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction of
May 12, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2011 Obagi Medical Product UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2011 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction of
May 12, 2011	EX-10.1	FIRST AMENDMENT TO AMENDED AND RESTATED REVOLVING CREDIT AND TERM LOAN AGREEMENT FIRST AMENDMENT TO AMENDED AND RESTATED REVOLVING CREDIT AND TERM LOAN AGREEMENT This First Amendment to Amended and Restated Revolving Credit and Term Loan Agreement (?Amendment?) is made as of this 4th day of May, 2011, by and among the financial institutions from time to time signatory hereto (individually a ?Lender,? and any and all such financial institutions collectively, the ?Lenders?), Comerica Bank, as Administrative Agent for the Lenders (in such capacity, the ?Agent?), Arranger, Syndication Agent and Documentation Agent, and Obagi Medical Products, Inc.
May 9, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33204 OBAGI MED
May 5, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2011 Obagi Medical Product UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2011 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction of
May 5, 2011	EX-99.1	Obagi Medical Products Reports First Quarter 2011 Results -Conference Call To Be Held at 4:30 PM EDT Today- [ Contact: Preston Romm CFO, EVP of Finance, Operations & Administration Obagi Medical Products, Inc.
April 28, 2011	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registran UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin
April 22, 2011	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2011 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction
April 22, 2011	EX-99.1	OBAGI MEDICAL PRODUCTS APPOINTS ALBERT F. HUMMEL PRESIDENT AND CEO Contact: Preston Romm CFO, EVP of Finance, Operations and Administration 562.628.1007 OBAGI MEDICAL PRODUCTS APPOINTS ALBERT F. HUMMEL PRESIDENT AND CEO LONG BEACH, Calif.?April 21, 2011?Obagi Medical Products, Inc. (NASDAQ: OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced that Albert F. Hummel has been appointed the Company?s President and Chief Executive
April 20, 2011	EX-10.1	Amendment No. 1 Amended and Restated Executive Employment Agreement Amendment No. 1 to Amended and Restated Executive Employment Agreement This Amendment No. 1 to Amended and Restated Executive Employment Agreement (the ?Amendment?) is entered into and effective as of the 15th day of April 2011 by and between Obagi Medical Products, Inc., a Delaware corporation (the ?Company?), and David S. Goldstein, an individual resident of the State of California (?Executive?)
April 20, 2011	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2011 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction
March 11, 2011	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33204 OBAGI MEDICAL
March 11, 2011	EX-10.38	2011 PERFORMANCE INCENTIVE PLAN (the ?Plan?) 2011 PERFORMANCE INCENTIVE PLAN (the ?Plan?) The 2011 Performance Incentive Plan amends, restates and is the successor plan to the 2010 Performance Incentive Plan, each of which was adopted under the Obagi Medical Products, Inc.
March 10, 2011	EX-99.1	Obagi Medical Products Reports Fourth Quarter Financial Results --Fourth Quarter GAAP EPS of $0.14 and Proforma EPS of $0.24 -- -Conference Call To Be Held at 4:30 PM EST Today- Contact: Preston Romm CFO, EVP of Finance, Operations & Administration Obagi Medical Products, Inc.
March 10, 2011	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2011 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction
February 10, 2011	EX-1	POWER OF ATTORNEY EX-1 2 a11-55801ex1.htm EX-1 Exhibit 1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints William Wolff and P. Yvonne Ying, each of O’Melveny & Myers LLP, or either of them, the undersigned’s true and lawful attorneys-in-fact to: (1) prepare, on the undersigned’s behalf, and submit to the United States Securities and Exchange Commission (the “SEC”) a
February 10, 2011	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 2)* OBAGI MEDICAL PRODUCTS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67423R 10 8 (CUSIP Number) December 3
February 8, 2011	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* Obagi Medical Products, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* Obagi Medical Products, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 67423R108 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate b
February 8, 2011	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Obagi Medical Products, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class o Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Obagi Medical Products, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 67423R108 (CUSIP Number) January 01, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box
November 19, 2010	POS EX	As filed with the Securities and Exchange Commission on November 19, 2010 As filed with the Securities and Exchange Commission on November 19, 2010 Registration No.
November 19, 2010	EX-99.1	OBAGI MEDICAL PRODUCTS ANNOUNCES PRICING OF SECONDARY OFFERING BY, AND REPURCHASE OF SHARES FROM, SELLING STOCKHOLDERS Exhibit 99.1 OBAGI MEDICAL PRODUCTS ANNOUNCES PRICING OF SECONDARY OFFERING BY, AND REPURCHASE OF SHARES FROM, SELLING STOCKHOLDERS LONG BEACH, Calif.—Nov. 19, 2010- Obagi Medical Products, Inc. (NASDAQ: OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced the pricing of the secondary public offering of 2,690,244 shares of its common stock by the Stonington Cap
November 19, 2010	424B4	2,690,244 shares Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-170129 Prospectus Supplement (To Prospectus dated November 15, 2010) 2,690,244 shares Common Stock The selling stockholders named in this prospectus supplement are offering an aggregate of up to 2,690,244 shares of our common stock. We will not receive any of the proceeds from the sale of any shares of our common stock by the selling stockholde
November 19, 2010	EX-1.1	2,690,244 Shares OBAGI MEDICAL PRODUCTS, INC. Common Stock UNDERWRITING AGREEMENT Exhibit 1.1 2,690,244 Shares OBAGI MEDICAL PRODUCTS, INC. Common Stock UNDERWRITING AGREEMENT November 18, 2010 STIFEL, NICOLAUS & COMPANY, INCORPORATED One Montgomery Street, Suite 3700 San Francisco, CA 94104 Ladies and Gentlemen: Certain stockholders of Obagi Medical Products, Inc., a Delaware corporation (the “Company”) named in Schedule II hereto (the “Selling Stockholders”), propose to sell
November 19, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2010 Obagi Medical P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2010 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdicti
November 15, 2010	CORRESP	November 15, 2010 November 15, 2010 VIA EDGAR United States Securities and Exchange Commission 100 F.
November 15, 2010	EX-99.1	Obagi Medical Products Announces Agreement to Repurchase $35 million of its Shares and Commencement of a Secondary Offering by Selling Stockholders Obagi Medical Products Announces Agreement to Repurchase $35 million of its Shares and Commencement of a Secondary Offering by Selling Stockholders LONG BEACH, Calif.
November 15, 2010	424B4	SUBJECT TO COMPLETION, DATED NOVEMBER 15, 2010 Filed Pursuant to Rule 424(b)(4) Registration No. 333-170129 The information in this prospectus supplement is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities i
November 15, 2010	S-1/A	As filed with the Securities and Exchange Commission on November 15, 2010 As filed with the Securities and Exchange Commission on November 15, 2010 Registration No.
November 15, 2010	EX-10.1	Stock Purchase Agreement Exhibit 10.1 Stock Purchase Agreement This Stock Purchase Agreement (this ?Agreement?), dated as of November 15, 2010, is by and among Obagi Medical Products, Inc., a Delaware corporation (the ?Company?), Stonington Capital Appreciation 1994 Fund, L.P., a Delaware limited partnership (?Stonington?), and The Zein and Samar Obagi Family Trust (the ?Obagi Trust,? and together with Stonington, the ?Se
November 15, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2010 Obagi Medical P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2010 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdicti
November 5, 2010	S-1/A	As filed with the Securities and Exchange Commission on November 5, 2010 As filed with the Securities and Exchange Commission on November 5, 2010 Registration No.
November 4, 2010	EX-10.36	AMENDED AND RESTATED REVOLVING CREDIT AND TERM LOAN AGREEMENT DATED AS OF NOVEMBER 3, 2010 OBAGI MEDICAL PRODUCTS, INC. OMP, INC. COMERICA BANK AS ADMINISTRATIVE AGENT AND LEAD ARRANGER Exhibit 10.36 AMENDED AND RESTATED REVOLVING CREDIT AND TERM LOAN AGREEMENT DATED AS OF NOVEMBER 3, 2010 OBAGI MEDICAL PRODUCTS, INC. AND OMP, INC. COMERICA BANK AS ADMINISTRATIVE AGENT AND LEAD ARRANGER Detroit10266307 TABLE OF CONTENTS 1 DEFINITIONS. 1 1.1 Certain Defined Terms 1 2 REVOLVING CREDIT. 22 2.1 Commitment 22 2.2 Accrual of Interest and Maturity; Evidence of Indebtedness. 22 2.3 Reque
November 4, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33204 OBAGI
November 4, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2010 Obagi Medical Pr UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2010 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdictio
November 4, 2010	EX-99.1	Obagi Medical Products' Third Quarter 2010 Net Sales Rise 12 Percent -Conference Call To Be Held at 4:30 PM EDT Today- Contact: Preston Romm CFO, EVP of Finance, Operations & Administration Obagi Medical Products, Inc.
November 4, 2010	CORRESP	November 5, 2010 November 5, 2010 VIA EDGAR United States Securities and Exchange Commission 100 F.
October 26, 2010	S-1	As filed with the Securities and Exchange Commission on October 26, 2010 As filed with the Securities and Exchange Commission on October 26, 2010 Registration No.
October 26, 2010	EX-10.35	SEPARATION AGREEMENT AND RELEASE EX-10.35 3 exhibit1035.htm STEVE CARLSON SEPARATION AGREEMENT Exhibit 10.35 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Steven R. Carlson (“Executive”) and Obagi Medical Products, Inc., a Delaware corporation (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Executi
October 26, 2010	EX-99.1	Obagi Medical Products Announces Proposed Secondary Offering by Selling Stockholders and Authorization to Repurchase Shares Obagi Medical Products Announces Proposed Secondary Offering by Selling Stockholders and Authorization to Repurchase Shares LONG BEACH, Calif.
October 26, 2010	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2010 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdictio
October 18, 2010	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2010 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction
October 18, 2010	EX-99.1	Obagi Medical Products Announces Changes to its Senior Management Contact: Preston Romm CFO, EVP of Finance, Operations & Administration Obagi Medical Products, Inc.
September 9, 2010	EX-99.1	OBAGI MEDICAL PRODUCTS GIVES NOTICE OF TERMINATION OF 2006 AGREEMENT WITH DR. ZEIN OBAGI AND RELATED PARTIES Exhibit 99.1 Contact: Preston Romm CFO, EVP of Finance, Operations & Administration Obagi Medical Products, Inc. 562.628.1007 OBAGI MEDICAL PRODUCTS GIVES NOTICE OF TERMINATION OF 2006 AGREEMENT WITH DR. ZEIN OBAGI AND RELATED PARTIES Long Beach, Calif. ? September 2, 2010 ? Obagi Medical Products, Inc. (NASDAQ: OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announ
September 9, 2010	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2010 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdicti
August 9, 2010	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33204 OBAGI MEDI
August 5, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2010 Obagi Medical Prod UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2010 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction
August 5, 2010	EX-99.1	OBAGI MEDICAL PRODUCTS’ SECOND QUARTER 2010 NET SALES ROSE 12 PERCENT --COMPANY RAISES FULL YEAR SALES GUIDANCE-- Contact: Preston Romm CFO, EVP of Finance, Operations & Administration Obagi Medical Products, Inc.
June 9, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2010 Obagi Medical Produc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2010 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction of
May 7, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33204 OBAGI MED
May 7, 2010	EX-10.37	2010 PERFORMANCE INCENTIVE PLAN (the “Plan”) EX-10.37 6 performanceplan.htm 2010 PERFORMANCE INCENTIVE PLAN Exhibit 10.37 2010 PERFORMANCE INCENTIVE PLAN (the “Plan”) The 2010 Performance Incentive Plan amends, restates and is the successor plan to the 2009 Performance Incentive Plan, which was adopted under the Obagi Medical Products, Inc. 2005 Stock Incentive Plan. PLAN PARTICIPANTS All regular, full-time employees of Obagi Medical Product
May 6, 2010	EX-99.1	OBAGI MEDICAL PRODUCTS’ FIRST QUARTER 2010 REVENUE ROSE 14%; NET INCOME INCREASED THREE-FOLD TO $1.9 MILLION --Management to Host Conference Call Today at 9:00 a.m. EDT (6:00 a.m. PDT) -- Contact: Preston Romm CFO, EVP of Finance, Operations and Administration Obagi Medical Products, Inc.
May 6, 2010	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2010 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction of
April 30, 2010	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin
March 30, 2010	EX-3	POWER OF ATTORNEY EXHIBIT 3 POWER OF ATTORNEY The undersigned, Daniel J. Donoghue, hereby appoints Mark Buckley his true and lawful attorney-in-fact and agent, with full power to execute and file with the United States Securities and Exchange Commission and any stock exchange or similar authority, for and on his behalf in any and all capacities, any and all reports required to be filed pursuant to Section 13 of the
March 30, 2010	SC 13D/A	UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.C. 20549 Expires: February 28, 2009 SCHEDULE 13D Estimated average burden hours per response. . 14.5 Under the Securities Exchange Act of 1934 (Amendmen UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.
March 30, 2010	EX-2	JOINT FILING AGREEMENT EXHIBIT 2 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Amendment No.
March 30, 2010	EX-1	TRANSACTIONS DURING PAST 60 DAYS EX-1 2 ex1.htm EXHIBIT 1 EXHIBIT 1 TRANSACTIONS DURING PAST 60 DAYS The Reporting Persons engaged in the following transactions in shares of Common Stock of the Company during the past 60 days. Such transactions involved the purchase of shares on the Nasdaq National Market System. The prices reported below reflect the weighted average purchase price of the shares of Common Stock purchased on the r
March 30, 2010	EX-4	POWER OF ATTORNEY EX-4 5 ex4.htm EXHIBIT 4 EXHIBIT 4 POWER OF ATTORNEY The undersigned, Michael R. Murphy, hereby appoints Mark Buckley his true and lawful attorney-in-fact and agent, with full power to execute and file with the United States Securities and Exchange Commission and any stock exchange or similar authority, for and on his behalf in any and all capacities, any and all reports required to be filed pursu
March 15, 2010	EX-10.11	August 6, 2007 Exhibit 10.11 August 6, 2007 Steve Carlson 615 Hurlingham Ave San Mateo Re: Amendment to Employment Agreement dated March 1, 2005 Dear Steve, On August 3, 2007, the Compensation Committee of the Board of Directors of Obagi Medical Products, Inc. (the "Company") adopted the 2007 Performance Incentive Plan (the "Plan"), attached hereto as Exhibit A, providing eligible employees with the potential to
March 15, 2010	EX-10.27	Third Amendment to Employment Agreement Exhibit 10.27 Third Amendment to Employment Agreement This Third Amendment to Employment Agreement (the ?Amendment?) is entered into as of December 31, 2008 between OMP, Inc., a Delaware corporation (?OMP?) and Steven R. Carlson (?Executive?). Recitals: Whereas, Executive and the Company are parties to an Employment Agreement entered into as of March 1, 2005, as amended by the First Amendment to E
March 15, 2010	EX-10.34	2009 PERFORMANCE INCENTIVE PLAN (the ?Plan?) Exhibit 10.34 2009 PERFORMANCE INCENTIVE PLAN (the ?Plan?) The 2009 Performance Incentive Plan amends, restates and is the successor plan to the 2008 Performance Incentive Plan, each of which was adopted under the Obagi Medical Products, Inc. 2005 Stock Incentive Plan. PLAN PARTICIPANTS All regular, full-time employees of Obagi Medical Products (the ?Company?) who have been notified in writing of
March 15, 2010	EX-10.35	SERVICE AGREEMENT Exhibit 10.35 The confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. REDACTED PORTIONS OF THIS EXHIBIT ARE INDICATED BY AN [###]. SERVICE AGREEMENT This Service Agreement (this ?Agreement?) is made as of
March 15, 2010	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33204 OBAGI MEDICAL
March 15, 2010	EX-10.36	Fourth Amendment to Employment Agreement Exhibit 10.36 Fourth Amendment to Employment Agreement This Fourth Amendment to Employment Agreement (the ?Amendment?) is entered into as of March 11, 2010 between OMP, Inc., a Delaware corporation (?the Company?) and Steven R. Carlson (?Executive?). Recitals: Whereas, Executive and the Company are parties to an Employment Agreement entered into as of March 1, 2005, as amended by the First Amendme
March 11, 2010	EX-99.1	OBAGI MEDICAL PRODUCTS’ FOURTH QUARTER 2009 REVENUE INCREASED 21% AND NET INCOME MORE THAN DOUBLED TO $4.8 MILLION Long Beach, Calif. — March 11, 2010 — Obagi Medical Products, Inc. (NASDAQ: OMPI) today reported net revenue for the fourth quarter end Contact: Preston Romm CFO, EVP of Finance, Operations and Administration Obagi Medical Products, Inc.
March 11, 2010	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2010 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction
February 12, 2010	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Obagi Medical Products (Name of issuer) COMMON STOCK, $.001 PER SHARE (Title of class of securities) (CUSIP number) De SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Obagi Medical Products (Name of issuer) COMMON STOCK, $.001 PER SHARE (Title of class of securities) 67423R108 (CUSIP number) December 31, 2009 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which th
January 11, 2010	EX-99.1	OBAGI MEDICAL PRODUCTS SERVED WITH COMPLAINT FROM ZO SKIN HEALTH, INC. Contact: Preston Romm Executive Vice President Finance & Administration Obagi Medical Products, Inc.
January 11, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2010 Obagi Medical Pro UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2010 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction
January 7, 2010	S-8	As filed with the Securities and Exchange Commission on January 7, 2010 As filed with the Securities and Exchange Commission on January 7, 2010 Registration No.
November 13, 2009	EX-3	POWER OF ATTORNEY EXHIBIT 3 POWER OF ATTORNEY The undersigned, Daniel J. Donoghue, hereby appoints Mark Buckley his true and lawful attorney-in-fact and agent, with full power to execute and file with the United States Securities and Exchange Commission and any stock exchange or similar authority, for and on his behalf in any and all capacities, any and all reports required to be filed pursuant to Section 13 of the
November 13, 2009	SC 13D	UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.C. 20549 Expires: February 28, 2009 SCHEDULE 13D Estimated average burden hours per response. . 14.5 Under the Securities Exchange Act of 1934 (Amendmen UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.
November 13, 2009	EX-1	TRANSACTIONS DURING THE PAST 60 DAYS EXHIBIT 1 TRANSACTIONS DURING THE PAST 60 DAYS The Reporting Persons engaged in the following transactions in shares of Common Stock of the Company during the past 60 days.
November 13, 2009	EX-2	JOINT FILING AGREEMENT EXHIBIT 2 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Schedule 13D to which this Agreement is attached.
November 13, 2009	EX-4	POWER OF ATTORNEY EXHIBIT 4 POWER OF ATTORNEY The undersigned, Michael R. Murphy, hereby appoints Mark Buckley his true and lawful attorney-in-fact and agent, with full power to execute and file with the United States Securities and Exchange Commission and any stock exchange or similar authority, for and on his behalf in any and all capacities, any and all reports required to be filed pursuant to Section 13 of the
November 6, 2009	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33204 OBAGI
November 6, 2009	EX-10.48	Amendment and Addendum Know-How and Trademark License Agreement The confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
November 6, 2009	EX-10.58	Amendment No. 2 to Distribution Agreement The confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
November 6, 2009	EX-10.57	AMENDED AND RESTATED PRODUCT SUPPLY AGREEMENT The confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
November 5, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2009 Obagi Medical Pr UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2009 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdictio
November 5, 2009	EX-99.1	OBAGI MEDICAL PRODUCTS REPORTS THIRD QUARTER 2009 EARNINGS Contact: Preston Romm CFO, EVP of Finance, Operations & Administration Obagi Medical Products, Inc.
October 15, 2009	CORRESP	October 15, 2009 October 15, 2009 UNITED STATES SECURITIES AND EXCHANGE COMMISSION 450 Fifth Street, N.
September 4, 2009	CORRESP	September 4, 2009 September 4, 2009 UNITED STATES SECURITIES AND EXCHANGE COMMISSION 450 Fifth Street, N.
August 7, 2009	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33204 OBAGI MEDI
August 6, 2009	EX-99.1	OBAGI MEDICAL PRODUCTS REPORTS SECOND QUARTER 2009 FINANCIAL RESULTS Contact: Preston Romm CFO, EVP of Finance, Operations & Administration Obagi Medical Products, Inc.
August 6, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2009 Obagi Medical Prod UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2009 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction
June 18, 2009	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2009 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction o
June 18, 2009	EX-10.56	Amended and Restated Executive Employment Agreement Exhibit 10.56 Amended and Restated Executive Employment Agreement This Amended and Restated Employment Agreement (this "Agreement"), is executed and delivered effective as of June 15, 2009 (the "Effective Date"), by and between Obagi Medical Products, Inc., a Delaware corporation (the "Company"), and Laura B. Hunter, an individual resident of the State of California ("Executive"). 1. Position And
June 18, 2009	EX-10.54	Amended and Restated Executive Employment Agreement Exhibit 10.54 Amended and Restated Executive Employment Agreement This Amended and Restated Employment Agreement (this "Agreement"), is executed and delivered effective as of June 15, 2009 (the "Effective Date"), by and between Obagi Medical Products, Inc., a Delaware corporation (the "Company"), and Preston S. Romm, an individual resident of the State of California ("Executive"). 1. Position And
June 18, 2009	EX-10.55	Amended And Restated Executive Employment Agreement Exhibit 10.55 Amended And Restated Executive Employment Agreement This Amended And Restated Employment Agreement (this "Agreement"), is executed and delivered effective as of June 15, 2009 (the "Effective Date"), by and between Obagi Medical Products, Inc., a Delaware corporation (the "Company"), and David S. Goldstein, an individual resident of the State of California ("Executive"). 1. Position A
June 18, 2009	EX-10.53	AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.53 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this "Agreement"), is executed and delivered effective as of June 15, 2009 (the "Effective Date"), by and between Obagi Medical Products, Inc., a Delaware corporation (the "Company"), and , an individual resident of the State of California ("Executive"). 1. POSITION AND RESPONSIBILITIES (a) Position. Execu
May 8, 2009	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33204 OBAGI MED
May 8, 2009	DEFR14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1 ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1 ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Def
May 8, 2009	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
May 7, 2009	EX-99.1	OBAGI MEDICAL PRODUCTS REPORTS FIRST QUARTER 2009 FINANCIAL RESULTS -- First Quarter of Rosaclear Launch Proves Successful -- Contact: Preston Romm CFO, EVP of Finance, Operations & Administration Obagi Medical Products, Inc.
May 7, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2009 Obagi Medical Product UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2009 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction of
April 30, 2009	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin
April 13, 2009	EX-99.1	OBAGI MEDICAL PRODUCTS, INC. FOCUSES ON THE PHYSICIAN DISPENSE MARKET AND DISCONTINUES DISTRIBUTION IN THE PHARMACY CHANNEL Contact: Preston Romm CFO, EVP of Finance, Operations and Administration Obagi Medical Products, Inc.
April 13, 2009	8-K	Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2009 Obagi Medical Products, Inc. (Exact name of registrant as specified in its charter) 001-33204 (Commission File Number) Delaware 22-3904668 (State or other jurisdiction of incorporati
March 13, 2009	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K 10-K 1 form10k2008.htm 2008 ANNUAL REPORT ON FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2008 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period f
March 13, 2009	EX-10.48	Amendment and Addendum Know-How and Trademark License Agreement This Amendment and Addendum to know-how and trademark license Agreement (the ?Amendment?) is entered into as of December 4, 2008 (the ?Amendment Date?) by and between, on the one hand, O Exhibit 10.48 The confidential portions of this exhibit have been filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN [##]. Amendment and Addendum to Know-How and Trademark License Agreement This Amendment and

OMPI / Obagi Medical Products, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)